SG
REGN icon

Sankala Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Sankala Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48K Sell
64
-1
-2% -$766 0.04% 235
2025
Q4 		$50.8K Buy
+65
New +$44.1K 0.04% 228

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sankala Group's REGN Position: Q1 2026 in Review

Sankala Group reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q1 2026, selling an estimated $766 and leaving 64 shares worth $48K. The position accounts for 0.04% of the portfolio, ranked #235.

Sankala Group first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $50.8K in Q4 2025. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Sankala Group held 64 shares of Regeneron Pharmaceuticals worth $48K as of Q1 2026.
  • Sankala Group sold 1 Regeneron Pharmaceuticals share in Q1 2026, an estimated $766.
  • Regeneron Pharmaceuticals made up 0.04% of Sankala Group's portfolio in Q1 2026, its #235 holding.
  • Sankala Group first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Regeneron Pharmaceuticals position peaked at $50.8K in Q4 2025.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.